Quantumleap Healthcare Collaborative
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 400
- Registration Number
- NCT06075953
- Locations
- 🇺🇸
Berkeley Outpatient Center, Berkeley, California, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Conditions
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 54
- Registration Number
- NCT05868226
- Locations
- 🇺🇸
The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois, United States
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Registration Number
- NCT04602117
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 1500
- Registration Number
- NCT04488081
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Conditions
- Interventions
- Drug: Standard TherapyDrug: AMG 386 with or without TrastuzumabDrug: AMG 479 (Ganitumab) plus MetforminDrug: MK-2206 with or without TrastuzumabDrug: T-DM1 and PertuzumabDrug: Pertuzumab and TrastuzumabDrug: GanetespibDrug: ABT-888Drug: NeratinibDrug: PLX3397Drug: Pembrolizumab - 4 cycleDrug: Talazoparib plus IrinotecanDrug: Patritumab and TrastuzumabDrug: Pembrolizumab - 8 cycleDrug: SGN-LIV1ADrug: Durvalumab plus OlaparibDrug: SD-101 + PembrolizumabDrug: Tucatinib plus trastuzumab and pertuzumabDrug: CemiplimabDrug: Cemiplimab plus REGN3767Drug: Trilaciclib with or without trastuzumab + pertuzumabDrug: SYD985 ([vic-]trastuzumab duocarmazine)Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabDrug: Dan222 + NiraparibDrug: Sarilumab + Cemiplimab + PaclitaxelDrug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumabDrug: AmcenestrantDrug: Amcenestrant + AbemaciclibDrug: Amcenestrant + LetrozoleDrug: ARX788Drug: ARX788 + CemiplimabDrug: VV1 + CemiplimabDrug: Datopotamab deruxtecanDrug: Datopotamab deruxtecan + DurvalumabDrug: ZanidatamabDrug: LasofoxifeneDrug: Z-endoxifenDrug: ARV-471Drug: ARV-471 + LetrozoleDrug: ARV-471 + AbemaciclibDrug: Endoxifen + AbemaciclibDrug: Rilvegostomig + TDXdDrug: AMG 386 and Trastuzumab
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 5000
- Registration Number
- NCT01042379
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Kansas, Westwood, Kansas, United States